Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Citius Oncology ( (CTOR) ) has shared an announcement.
On April 22, 2026, Citius Oncology disclosed that it received a notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering non-compliance with Nasdaq’s listing requirements. The company has until October 19, 2026, to regain compliance, potentially through measures such as a reverse stock split, and while its shares remain listed for now, failure to remedy the deficiency could ultimately lead to delisting proceedings, with implications for liquidity and investor confidence.
Nasdaq’s notice does not immediately affect trading in Citius Oncology’s stock, which continues to trade under the CTOR symbol during the 180-day grace period. However, if the company cannot restore the bid price to at least $1.00 for the required period, it may seek an additional compliance window or appeal any delisting decision, leaving shareholders facing heightened uncertainty over the stock’s long-term market status.
The most recent analyst rating on (CTOR) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Citius Oncology stock, see the CTOR Stock Forecast page.
Spark’s Take on CTOR Stock
According to Spark, TipRanks’ AI Analyst, CTOR is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and rising cash burn implying financing risk). Positive corporate events around LYMPHIR commercialization and early clinical signals provide an offset, while technicals are mixed and valuation metrics are not supportive due to ongoing losses and no dividend.
To see Spark’s full report on CTOR stock, click here.
More about Citius Oncology
Citius Oncology, Inc. operates in the biotechnology and pharmaceutical sector, focusing on oncology-related therapies and products. The company’s common stock is listed on the Nasdaq Capital Market under the ticker symbol CTOR, giving it access to public equity markets for funding its clinical and operational programs.
Average Trading Volume: 259,473
Technical Sentiment Signal: Sell
Current Market Cap: $77.43M
See more data about CTOR stock on TipRanks’ Stock Analysis page.